ACHE and early-onset autosomal dominant Alzheimer disease: Where the metabolism of beta-amyloid precursor has been attributed to cholinergic hyperactivity,68 given its effects on beta-amyloid metabolism, there is a potential for AChE inhibitors to be used as a clinical neuroprotective therapy for neurological disorders like senile dementia, ataxia, myasthenia gravis, and Alzheimer’s disease.69–71